by B2i | Sep 10, 2021 | Press Releases
JUPITER, Fla., Sept. 10, 2021 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying, and...
by B2i | Aug 12, 2021 | Press Releases
Executed binding term sheet with Sorrento Therapeutics (Nasdaq:SRNE) to outlicense C1 protein production platform for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including...
by B2i | Aug 11, 2021 | Press Releases
Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic’s C1 technology for the development and commercialization of vaccines, therapeutic...
by B2i | Jul 29, 2021 | Press Releases
JUPITER, FL / July 29, 2021 / Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its...
by B2i | Jul 27, 2021 | Press Releases
Potential for Affordable COVID-19 Immunization Coverage in Underserved African CountriesArrangement includes C1 COVID-19 vaccine technology transfer and licensing agreementProvides potential funding pathway for a C1 manufactured COVID-19 vaccine to progress through...